Form 8-K - Current report:
SEC Accession No. 0001628280-25-029646
Filing Date
2025-06-05
Accepted
2025-06-05 16:11:50
Documents
13
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20250604.htm   iXBRL 8-K 33160
  Complete submission text file 0001628280-25-029646.txt   186440

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20250604.xsd EX-101.SCH 2054
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prme-20250604_def.xml EX-101.DEF 15891
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20250604_lab.xml EX-101.LAB 27927
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20250604_pre.xml EX-101.PRE 16657
15 EXTRACTED XBRL INSTANCE DOCUMENT prme-20250604_htm.xml XML 2913
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 251027224
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)